PL4062912T3 - Półuwodniony monokryształ utidelonu oraz sposób jego wytwarzania i zastosowanie - Google Patents

Półuwodniony monokryształ utidelonu oraz sposób jego wytwarzania i zastosowanie

Info

Publication number
PL4062912T3
PL4062912T3 PL21783766.5T PL21783766T PL4062912T3 PL 4062912 T3 PL4062912 T3 PL 4062912T3 PL 21783766 T PL21783766 T PL 21783766T PL 4062912 T3 PL4062912 T3 PL 4062912T3
Authority
PL
Poland
Prior art keywords
utidelone
semi
preparation
single crystal
method therefor
Prior art date
Application number
PL21783766.5T
Other languages
English (en)
Inventor
Li Tang
Rixiang KONG
Rongguo Qiu
Original Assignee
Beijing Biostar Pharmaceuticals Co., Ltd.
Chengdu Biostar Pharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Biostar Pharmaceuticals Co., Ltd., Chengdu Biostar Pharmaceuticals, Ltd. filed Critical Beijing Biostar Pharmaceuticals Co., Ltd.
Publication of PL4062912T3 publication Critical patent/PL4062912T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL21783766.5T 2020-04-08 2021-04-08 Półuwodniony monokryształ utidelonu oraz sposób jego wytwarzania i zastosowanie PL4062912T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010282801 2020-04-08
PCT/CN2021/085903 WO2021204188A1 (zh) 2020-04-08 2021-04-08 优替德隆半水合物单晶及其制备方法与应用

Publications (1)

Publication Number Publication Date
PL4062912T3 true PL4062912T3 (pl) 2024-06-17

Family

ID=78022766

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21783766.5T PL4062912T3 (pl) 2020-04-08 2021-04-08 Półuwodniony monokryształ utidelonu oraz sposób jego wytwarzania i zastosowanie

Country Status (8)

Country Link
US (1) US12617781B2 (pl)
EP (1) EP4062912B1 (pl)
JP (3) JP2023509871A (pl)
CN (1) CN114727994B (pl)
ES (1) ES2981166T3 (pl)
HU (1) HUE066421T2 (pl)
PL (1) PL4062912T3 (pl)
WO (1) WO2021204188A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505154A (ja) * 2021-12-31 2024-02-05 成都華昊中天薬業有限公司 ウチデロンリポソーム組成物、及びその製造方法並びに使用
CN117731661A (zh) * 2023-11-30 2024-03-22 上海市第一人民医院 优替德隆在胰腺癌的应用
WO2026032322A1 (zh) * 2024-08-06 2026-02-12 北京华昊中天生物医药股份有限公司 优替德隆治疗实体肿瘤的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US20030004338A1 (en) * 2001-02-01 2003-01-02 Li Wen Sen Process for the preparation of epothilone analogs
CN101177425B (zh) * 2003-01-28 2012-07-18 北京华昊中天生物技术有限公司 一类新型埃坡霉素化合物及其制备方法和用途
CN101519404B (zh) * 2008-02-29 2016-01-20 唐莉 15环噻酮衍生物及其制备方法与应用
CN102101863B (zh) * 2009-12-17 2014-10-15 唐莉 新型环氧噻酮化合物及其制备方法和用途
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用

Also Published As

Publication number Publication date
EP4062912A4 (en) 2022-12-28
JP2026004563A (ja) 2026-01-14
US20230041956A1 (en) 2023-02-09
HUE066421T2 (hu) 2024-08-28
EP4062912C0 (en) 2024-04-03
US12617781B2 (en) 2026-05-05
EP4062912B1 (en) 2024-04-03
WO2021204188A1 (zh) 2021-10-14
ES2981166T3 (es) 2024-10-07
CN114727994A (zh) 2022-07-08
JP2023509871A (ja) 2023-03-10
EP4062912A1 (en) 2022-09-28
CN114727994B (zh) 2024-05-24
JP2024088796A (ja) 2024-07-02

Similar Documents

Publication Publication Date Title
ZA202202932B (en) Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
EP4040493A4 (en) DISPLAY DEVICE USING MICRO-LEDS AND METHOD FOR MANUFACTURING SAME
HUE066421T2 (hu) Félhidratált utidelon monokristály és annak elõállítási módszere, valamint felhasználása
EP4059926A4 (en) CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF
EP4013073A4 (en) DISPLAY DEVICE AND METHOD OF OPERATION
EP3911036A4 (en) MEASUREMENT PROCESS AND DEVICE
PL4072808T3 (pl) Wspomagany komputerowo sposób i układ do badania jakości betonu licowego
ZA202204143B (en) Film and preparation method thereof
EP3988072A4 (en) MEDICAL VEST AND METHOD OF USE
EP4120754A4 (en) CLOCK CALIBRATION METHOD AND APPARATUS
SG10201900431QA (en) A sterile reagent preparation device and the method of using the same
EP3736273A4 (en) NEW ACALABRUTINIB CRYSTAL FORM AND THE MANUFACTURING METHOD AND USE OF IT
EP3913021A4 (en) MEDICAL MATERIAL AND MANUFACTURING PROCESS THEREOF
SG10201910855WA (en) Display device and manufacturing method of polarizer structure
EP3741746A4 (en) CRYSTAL FORM OF OXOPICOLINAMIDE DERIVATIVE AND MANUFACTURING PROCESS FOR IT
GB201914724D0 (en) Method and apparatus for clinical testing
ZA202108765B (en) Pyridone derivative crystal form and preparation method and application therefor
ZA202201160B (en) Anti-grp78 antibodies and method of use thereof
ZA202201969B (en) Magnesium niobate single-crystal nanosheet and preparation method and application thereof
EP3747871A4 (en) CRYSTAL FORM OF THE URATTRANSPORTER-1 INHIBITOR AND METHOD FOR ITS MANUFACTURING AND USE
IL325591A (en) Crystalline form of bexdrostat and method for its preparation and use
IL326072A (en) Crystalline form of bazuclatinib, method for its preparation and use
GB2633066B (en) Display device and method
GB2622939B (en) Display device and method
GB2623339B (en) Display device and method